Compare Moderna, Inc. (MRNA) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs OneSpan Inc — how do they compare? Moderna, Inc. trades at $63.69 (market cap $24.18B), while OneSpan Inc trades at $16.57 (market cap $600.69M). The key difference: Moderna, Inc. is far larger — about 40.3× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | OSPN | |
|---|---|---|
Market Cap | $24.18B | $600.69M |
Sector | Health | Technology |
52-Week High | $81.80 | $16.78 |
52-Week Low | $22.36 | $10.15 |
Enterprise Value | $20.33B | $569.77M |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
OneSpan (OSPN) trades at $16.53, up 0.98% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a net income margin of 27.76% and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and the launch of DigipassONE, supporting growth in subscription revenue.
Outlook remains positive with a consensus price target of $17.00, though risks include declining net cash flow and competitive pressures. The stock offers value with a P/E of 9.21, but investors should monitor execution on guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
